Inhibiting the action of a particular enzyme called polymerase theta, or PolQ, dramatically slows the growth of tumor cells tied to BRCA1 and BRCA2 genetic mutations which, in turn, are closely tied to breast and ovarian cancers, according to a new paper. Senior investigator and NYU Langone cell biologist Agnel Sfeir, PhD, says that if further experiments prove successful, these findings could lead to a new class of targeted therapies against cancers with BRCA1 and BRCA2 mutations.
http://ift.tt/1HTLsdz
http://ift.tt/1HTLsdz
No comments:
Post a Comment